| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced an update on the status of its appeal against the determination of the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") to delist the Company's common shares ("Common Shares").
As previously disclosed, the Company had been notified by Nasdaq on November 30, 2023 that it was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (NASDAQ Listing Rule 5550(a)(2)), as the bid price for the Common Shares on Nasdaq closed below US$1.00 for 30 consecutive trading days and that it was not in compliance with the minimum stockholders' equity requirement (NASDAQ Listing Rule 5550(b)(1)), as the Company's stockholders' equity was below the minimum US$2.5 million required for continued listing. The Company submitted a request for a hearing to the to the Nasdaq Hearings Panel (the "Panel") to appeal the delisting determination.
The Panel hearing took place on February 29, 2024. On March 5, the Company received a written decision of the Panel pursuant to which the Panel upheld the delisting determination and denied the Company's requests for additional time to rectify the deficiencies. The Company has the right to request a review of the Panel Decision from the Nasdaq Listing Council within 15 days from the date of the Panel Decision.
The trading of the Company's Common Shares on Nasdaq will be suspended as of the opening of business on March 7, 2024. The Company is seeking to have its Common Shares quoted on the OTCQB® Venture Market of the OTCMarkets.
